Management of Insulin Resistance with Normal HbA1c

Initial Assessment and Approach

For patients with insulin resistance and normal HbA1c levels, lifestyle modifications including weight reduction, dietary changes, and increased physical activity should be the primary management approach, with consideration of metformin in selected cases, as recommended by the American Diabetes Association 1, 2
Insulin resistance, even without elevated HbA1c, increases risk for adverse cardiovascular outcomes and may progress to type 2 diabetes if not addressed, according to the American Diabetes Association 3
Treatment should focus on improving insulin sensitivity through lifestyle modifications as the cornerstone of management, with a goal to prevent progression to diabetes and reduce cardiovascular risk factors associated with insulin resistance, as stated by the American Diabetes Association 2, 3, 4

Establish a goal of modest weight reduction (5-10%) or at least weight maintenance, as this meaningfully improves insulin sensitivity, as recommended by the American Diabetes Association 2, 4
Promote as much physical activity as possible, ideally aiming for at least 150 minutes/week of moderate activity, including aerobic, resistance, and flexibility training, as suggested by the American Diabetes Association 2, 4

Metformin is the preferred first-line pharmacological agent for insulin resistance even with normal HbA1c, as recommended by the American Diabetes Association 5, 6
Metformin primarily works by reducing hepatic glucose production, is generally weight-neutral, and does not increase hypoglycemia risk, according to the American Diabetes Association 4, 5

Regular follow-up to assess adherence to lifestyle modifications and monitor for development of diabetes with periodic HbA1c testing is recommended by the American College of Physicians 2, 8
Assess other cardiovascular risk factors including blood pressure and lipid profiles, as suggested by the American Diabetes Association 3

Avoid aggressive glycemic targets in patients with advanced age, multiple comorbidities, or limited life expectancy, as recommended by the American Diabetes Association and the American College of Physicians 1, 9
Consider the patient's preferences, needs, and values in all treatment decisions, as stated by the American Diabetes Association 6